Charles River NGS Services Power Arovella Therapeutics’ ALA-101 Cell Therapy Manufacturing
Charles River Laboratories will supply GMP-grade Next Generation Sequencing (NGS) and viral safety release testing to Arovella Therapeutics for its ALA-101 CAR-iNKT cell therapy. The tie-up follows FDA acceptance of NGS-based viral safety testing in Arovella’s IND for treating CD19+ B-cell lymphomas and leukemias.
